OCS-01 in Diabetic Macular Edema (DIAMOND 1)

Market
100%75%50%25%0%Apr 26 • YES 48.0%Apr 26
Trade

Will this trial meet its primary endpoint?

Paper Trading
Create account to trade
DetailsModel PositionsModel SnapshotsOracle
Primary Completion
4/1/26
Study Completion
4/1/26
Sponsor
Oculis
Ticker
Unavailable
Type
Phase 2/Phase 3
Trial Status
Active Not Recruiting
Trial Size
552
NCT
NCT05066997
Trial Description
Phase 2/3 double-masked, randomized, two-stage, multicenter study evaluating topical OCS-01 versus vehicle in participants with diabetic macular edema. The trial’s primary endpoint is mean change in best corrected visual acuity measured by ETDRS letters at Week 52, with safety also assessed through Week 52.